Market closed

Entrada Therapeutics/$TRDA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Entrada Therapeutics

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Ticker

$TRDA
Trading on

Industry

Biotechnology

Employees

177

TRDA Metrics

BasicAdvanced
$635M
Market cap
11.56
P/E ratio
$1.55
EPS
-0.27
Beta
-
Dividend rate
$635M
-0.27
$19.64
$10.75
126K
6.591
6.418
12.682
14.514
6.95%
16.43%
11.561
2.952
1.5
1.5
-36.378
146.92%
-331.32%
-63.38%

What the Analysts think about TRDA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.

TRDA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TRDA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TRDA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Entrada Therapeutics stock?

Entrada Therapeutics (TRDA) has a market cap of $635M as of November 22, 2024.

What is the P/E ratio for Entrada Therapeutics stock?

The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 11.56 as of November 22, 2024.

Does Entrada Therapeutics stock pay dividends?

No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Entrada Therapeutics dividend payment date?

Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.

What is the beta indicator for Entrada Therapeutics?

Entrada Therapeutics (TRDA) has a beta rating of -0.27. This means that it has an inverse relation to market volatility.